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Background: The prognosis for patients with ductal adenocarcinoma of the pancreas (PDAC) remains
poor even after curative resection. Carbohydrate antigen 19-9 (CA 19-9) and the carcinoembryonic an-
tigen (CEA) are the most widely used serum-based tumor markers for the diagnosis and follow up of
pancreatic cancer. In our analysis we aim to assess the prognostic value of a combination of both tumor
markers in patients with pancreatic ductal adenocarcinoma (PDAC).
Patients and methods: Between 01/1995 and 08/2012 we performed a total of 264 pancreatic resections
due to PDAC. Patients were stratiﬁed into 3 groups in regard to their preoperative tumor marker levels.
Survival was compared between the groups using Kaplan Meier analysis and log rank test. Univariate
subgroup analysis and multivariate analysis were performed.
Results: For 259 cases complete follow up could be obtained. In patients with low preoperative CEA and
CA 19-9 levels (group 1 n ¼ 91) the mean survival was 33.3 month (CI 95% 25.1e41.5). If one of the
analyzed tumor markers (CEA/CA19-9) was preoperatively elevated above the cut-off level (group 2
n ¼ 106) mean survival was 28.5 month (CI 95% 22.1e35.1). 62 patients showed preoperative elevation of
both, CEA and CA 19-9 (group 3); mean survival in this group was 23.9 month (CI 95% 13.9e33.9),
p > 0.01. Multivariate analysis conﬁrmed preoperative CEA/CA 19-9 level as independent prognostic
factor (HR 1.299).
Conclusion: Preoperative CEA and CA 19-9 levels correlate with patient prognosis after curative
pancreatic resection due to PDAC. This is especially true for the most frequently pT 3/4 stages of PDAC.
Even if CEA and CA 19-9 might not be appropriate for screening, its serum levels should therefore be
determined prior to operation and taken into account when resectability or operability is doubtful.
 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
The prognosis for patients with ductal adenocarcinoma of the
pancreas (PDAC) remains poor. Today, tumor resection is the only
therapeutic option to achieve long-term survival.
However, only a small number of patients (30e40%) present
with a resectable tumor at the time of diagnosis.1,2 The overall 5-
year survival after pancreatic head resection for cancer has been
reported to range between 10 and 25%.3e5 An adjuvantoma; CEA, carcinoembryonic
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ciates Ltd. Published by Elsevier Ltchemotherapy, which improves patient survival, should be
routinely used.6,7 However, there are patients that relapse shortly
after the tumor resection and, therefore, have only a limited life
span even after R0 resection. Clinical parameters that have been
reported to be the signiﬁcant prognostic factors for patient survival
after tumor resection are as follows: age, tumor size, nodal and
margin status and tumor grade.4,8e10
Imagingmethods are not accurate enough to detect early lesions
and also the differentiation of malignant from benign pancreatic
lesions is an ordinary problem. For this the evaluation of molecular
markers for early detection of pancreatic cancer is essential. An
“ideal” tumormarker possesses high sensitivity enabling to identify
the disease in a screening population without symptoms. Further-
more the marker should be useful for staging, prognosis, evaluation
of response to therapy and follow up of PDAC.
A wide variety of tumor- and biomarkers in the serum,
pancreatic tissue, pancreatic juice and stool have been studiedd. All rights reserved.
Table 1
Demographics and pathohistological data of patient cohort (n ¼ 259) and stratiﬁ-
cation in regard to the preoperative CEA and CA 19-9 levels (Group 1e3).
Group 1
(n ¼ 91)
CEA/CA
19-9 below
cut-off level
Group 2
(n ¼ 106)
CEA or CA
19-9 above
cut-off
level
Group 3
(n ¼ 62)
CEA/CA 19-9
above
cut-off level
p-Value
Sex n ¼ (m/f) 49/42 62/44 33/29 0.534a
Age y (SD) 62.5 (12.2) 63.2 (12.4) 67.4 (12.1) 0.657a
Mean-survival
(month)
33.3 (CI 95%
25.1e41.5)
28.5 (CI 95%
22.1e35.1)
23.9 (CI 95%
13.9e33.9)
0.013a
Tumor localization
Head 79 81 49 0.743a
Body 4 6 2
Tail 8 19 11
Type of surgery
Head resections 77 79 46 0.411a
Total Pancreatect 4 5 2
Left resections 9 17 12
Others 1 5 2
pT 1/2 5 19 2 0.004a
pT 3/4 63 79 57
pN 0 23 35 21 0.987a
pN þ 43 61 38
pM 0 64 91 55 0.952a
pM þ 5 8 4
G 1/2 42 46 33 0.121a
G 3/4 24 51 26
R 0 65 73 46 0.876a
R 1 22 26 13
R 2 4 5 1
R x e 2 2
a ChieQuadrat Test.
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often limited by poor sensitivity, high false positive rates and lack of
large scale validation.12 Currently, the assessment of the serum
tumor markers CA 19-9 and CEA offer the best clinical use in PDAC.
1.1. CA 19-9
The carbohydrate antigen 19-9 (CA 19-9) is the most widely
assessed serum-based tumor marker for the diagnosis and follow up
of PDAC.13 CA 19-9 is a tumor associated antigen, initially isolated as a
colorectal cancer antigen, but also presented in epithelial cells of the
gallbladder, biliary system, pancreas and stomach.11,14 CA 19-9 is
related to the Lewis blood group antigens and only the 90e95% of
patients belonging to the Le (abþ) or Le (aþb) blood groups will
express theCA19-9antigen.15,16ThediagnosticvalueofCA19-9 for the
detection of PDAC has been demonstrated in several studies.13,15,17e20
SensitivityofCA19-9 rangesbetween69%and93%.Accordingly, about
30% of the patients with PDAC do not show elevated levels of CA 19-
9.13,19,20 Speciﬁcity for PDAC reaches up to 90%witha cutoff level at 37
U/ml.21 Notably, in regard to the differential diagnoses in PDACs, CA
19-9 can also be elevated in patients with liver cirrhosis and benign
inﬂammatory or cholestatic diseases of the pancreaobiliary tract.21,22
Unfortunately, due to lower levels in localized PDACs, CA 19-9 is not
useful for the early detection of small tumors.19,21
In clinical practice, CA 19-9 is most commonly used for assess-
ment of prognosis and monitoring of response or recurrence of a
PDAC.13,23
1.2. CEA
The carcinoembryonic antigen (CEA) was the ﬁrst tumor marker
used for diagnostics of PDACs starting in the seventies. After de-
cades, CEA nowadays has been replaced by markers with a higher
diagnostic performance such as CA 19-9. However, several recent
studies report low levels of CEA in normal tissue and elevated levels
in presence of pancreatic cancer.24,25 Speciﬁcity of CEA is up to 100%
with a range between 25 and 56%.24,26e28 Today CEA is mostly used
for the analysis of the ﬂuid of cystic pancreatic lesions (e.g. IPMN of
the pancreas). Elevated levels of CEA in the cyst ﬂuid are predictive
for malignancy in IPMN of the pancreas.29
In this study we aimed to investigate the prognostic value of the
preoperative tumor markers CEA and CA 19-9 alone or in combi-
nation in patients with PDAC.
2. Patients and methods
2.1. Patients
Between 01/1995 and 08/2012 we performed a total of 1251
pancreatic operations at our institution. Two hundred sixty-four
pancreatic resections were performed for PDAC with curative
intent. In 259 cases complete follow up could be obtained. Eight
hepatobiliary surgeons performed n ¼ 202 pancreatic head re-
sections (PPPD/Whipple), n ¼ 38 distal pancreatectomies, n ¼ 11
total pancreatectomies and n ¼ 8 other pancreatic resections
(segmental or central pancreatic resections). Tumor localizations
were: n¼ 209 head tumors, n¼ 38 tumors in the tail of the pancreas
and n ¼ 12 tumors in the body of the pancreas. In all cases, the
diagnosis of PDACwas conﬁrmed by postoperative histopathological
examination of the specimen. For this retrospective analysis we
excluded patients who underwent palliative pancreatic resections
for PDAC or patients with distal cholangiocarcinoma, duodenal
carcinoma, neuroendocrine tumors, cyst-adenocarcinoma, solid and
papillary tumors, and metastatic disease. Included patients were
stratiﬁed into 3 groups in regard to their preoperative CEA and CA19-9 levels (Group 1: CEA/CA 19-9 within normal ranges, Group 2:
CEA or CA 19-9 above the cut off level and Group 3: CEA and CA 19-9
both above cut off level) [Table 1].
2.2. Tumor marker measurements
Peripheral venous blood samples were taken from every patient
at time of presentation before any therapeutic procedure. These
samples were centrifuged and stored at 20 C until they were
analyzed. CEA and CA 19-9 analysis was performed with Liaison
Analyzer by Dia-Sorin (2-step sandwich chemiluminescence
immunoassay, using directly coated magnetic particles (solid
phase) and an isoluminol derivative (conjugate), (Dia-Sorin Diag-
nostic Group, Dietzenbach, Germany, http://www.diasorin.com).
2.3. Data collection
The medical records from a prospective database of patients
who underwent a pancreatic resection for PDAC were analyzed
retrospectively for each case. In accordance with the guidelines for
human subject research, approval was obtained from the Ethics
committee at the Carl Gustav Carus University Hospital. All oper-
ated patients signed informed consent before surgery. The survey
data were complemented with the clinical notes of the patients’
physicians and surgeons. The information regarding the deceased
patients was obtained from family members or from their general
practitioner. Patients were followed up until death; median post-
operative follow-up time was 38 month.
2.4. Statistical analysis
The preoperative tumor marker levels of CEA and CA 19-9 were
correlated with the patients clinical characteristics from our pro-
spective pancreatic database. The statistical analyses were
M. Distler et al. / International Journal of Surgery 11 (2013) 1067e1072 1069
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cago, IL). All clinical and pathological characteristics were stratiﬁed
to build categorical or nominal variables. Categorical data were
analyzed using Chi Square test. The estimates of patient survival
were generated using the KaplaneMeier method. Continuous data
are presented as 95% conﬁdence intervals (95% CI) and/or standard
deviation (SD). Survival is described as mean or median survival
with CI 95%. The comparisons of survival were made using the log-
rank test. Next, we performed a subgroup analysis for the different
tumor T-stages in correlation to CEA/CA 19-9 level. For multivariate
analysis we used a Cox regression analysis with stepwise back-
wards elimination based on the likelihood ratios to test for inde-
pendent predictors of survival.
Cut-off levels for CEA and CA 19-9 were determined at 3 ng/ml
and 75 U/ml, respectively (as recommended by themanufacturer of
the test kits). A p-value <0.05 was considered signiﬁcant.
3. Results
3.1. Patient cohort
From 01/1995 to 08/2012, 264 patients underwent pancreatic
resections due to ductal adenocarcinoma of the pancreas. As
mentioned above the 259 patients with complete follow up were
distributed to groups 1-3 according to their preoperative CEA and CA
19-9 levels. A total of ﬁve patients were excluded from the analysis
due to incomplete information on the preoperative tumor markers,
missing follow up after resection or incomplete tumor staging. In 91
cases preoperative CEA andCA19-9 valueswere both under the used
cut-off levels (group 1), in 106 patients either CEA or CA 19-9 were
above the cut-off level anda total of 62patients showedpreoperative
elevation of CEA and CA 19-9 [Table 1]. The three groups of patients
were comparable in regard to age and sex.However, in concern to the
tumor t-staging statistical analysis showed signiﬁcant differences
betweenthe3groups (p¼0.004) [Table1]. Thereforeweperformeda
subgroup analysis for the pT 1/2 and pT3/4 patients [Table 2].
3.2. Preoperative tumor marker level and survival
For each group we performed a Kaplan Meier analysis and com-
parisonsbetween thegroupsweremadeby the log rank test [Fig.1]. In
patients with low preoperative CEA and CA 19-9 levels (Group 1
n ¼ 91) the mean survival was 33.3 month (CI 95% 25.1e41.5) after
curative resection of a PDAC. If one of the analyzed tumor markers
(CEA/CA19-9) was elevated above the cut-off level preoperatively,
patients were classiﬁed into group 2 (n¼ 106). The estimated overall
survival for patients of Group 2was 28.5month (CI 95% 22.1e35.1). In
62 patients CEA and CA 19-9 were both elevated (Group 3) above the
cut off level of 3 ng/ml and 75 U/ml, respectively. Preoperative
elevationofboth tumormarkerswasassociatedwithapoorer survival
(23.9 month (CI 95% 13.9e33.9) for Group 3) [Fig. 1]. Log rank test
showed signiﬁcant differences (p < 0.01) between these 3 groups.
3.3. Univariate analysis
Due to statistical differences concerning t-staging (p ¼ 0.004)
between the 3 groups a univariate subgroup analysis of the patientsTable 2
Univariate analysis of median survival for T-stage subgroups and subgroups of CEA/CA 1
Subgroups Group 1 CEA/CA 19-9 below
cut-off level
pT 1/2 (n ¼ 26) Median-Survival (month) 25,9 (CI 95% 10.9e41,7)
pT 3/4 (n ¼ 199) Median-Survival (month) 27.7 (CI 95% 15.2e40.1)with pT 1/2 and pT3/4 tumors was performed. Univariate analysis
of subgroup pT 1/2 (n ¼ 26) showed a median survival of 25.9
months for group 1 and 17.1 months for group 2 patients as 8.3
months for group 3, respectively [Fig. 2]. In the pT 1/2 subgroup no
statistical signiﬁcance between the different CEA/CA19-9 groups
(1e3) was detected (p ¼ 0.109) [Table 2]. Subgroup analysis for pT
3/4 tumors (n ¼ 199) showed that preoperative tumor marker level
of CEA and CA 19-9 is an independent predictor of patient survival
(p ¼ 0.007) [Table 2]. Median survival of the pT 3/4 subgroup was;
27.7 months for group 1, 19.7 months for group 2 and 13.8 months
for group 3 [Fig. 3].
3.4. Multivariate analysis
Available clinical data which may inﬂuence patients median
survival (q.v. Table 1) was tested using a multivariate analysis.
There, preoperative elevation of CEA/CA 19-9 above the cut off
levels (p< 0.001), pT 1/2 stage (p¼ 0.040) and positive nodal status
(pNþ) (p ¼ 0.031) could be identiﬁed as independent factors
inﬂuencing patients survival after pancreatic resection (HR 1.299,
0.595 and 1.470, respectively).
4. Discussion
The aim of this study was to clarify the role of preoperative CEA/
CA 19-9 measurement as a prognostic marker after curatively
intended resection of a PDAC. Levels of CEA and CA 19-9 have been
widely described to be elevated in up to 85% of the patients with
PDAC.13,20,24,27,30 CEA and CA 19-9 can predict survival after
pancreatic resection and are markers for recurrent disease after
curative resection of a PDAC.24,31 Speciﬁcity of CEA and CA 19-9 for
PDAC ranges between 90 and 100%.21,26,27
The main problem of both markers, and especially for CEA, is a
low and wide-ranging sensitivity (30e90%) for detection of a
PDAC.13,19,20,24 About 60% of the patients with PDAC do not have
elevated levels of CEA and 30% do not show elevation of CA 19-
9.13,19,20 These ﬁndings could be conﬁrmed by our analysis. In our
cohort about 35% (Group 1 n ¼ 91) of the patients with PDAC
(Group 1, n ¼ 91) presented without any preoperative elevation of
CEA or CA 19-9.
Furthermore, CA 19-9 and CEA undergo biliary excretion, and
serum levels may be artiﬁcially increased due to liver cirrhosis and
benign inﬂammatory or cholestatic diseases of the pancreaobiliary
tract.21,22,32,33 However, elevated serum levels of CA 19-9 and CEA
correlate with tumor differentiation and extent of a PDAC.13,19,20,34
Unfortunately, due to the low levels in localized PDACs, CA 19-9 and
CEA are not useful for early detection of small tumors.19,21 Due to
this ﬁndings we, as other authors, do not advocate CEA or CA 19-9
as a screening tool for PDAC in asymptomatic patients.24
The merit of CEA and CA 19-9 to provide meaningful prognostic
information and allow for patient stratiﬁcation into survival groups
has been investigated before.20,34e39 Unique in our analysis is the
stratiﬁcation of the patients into 3 groups according to their pre-
operative levels of CEA and CA 19-9. We found that preoperative
tumor marker values below the cut off level (CEA 3 ng/ml and CA
19-9 75 U/ml) correlate with an improved survival after curative
resection of a PDAC. The mean survival for these patients (group 1)9-9 (Groups 1e3).
Group 2 CEA or CA 19-9
above cut-off level
Group 3 CEA/CA 19-9
above cut-off level
p-Value (log rank)
17,1 (CI 95% 4.9e29.2) 8.3 (CI 95% n.a.) 0.190
19.7 (CI 95% 15.4e24.1) 13.8 (CI 95% 10.8e16.8) 0.007
Fig. 1. Kaplan Meier analysis of patients with PDAC in regard to their preoperative levels of CEA and CA 19-9 (Group1-3).
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marker values above the cut off levels led to a more unfavorable
prognosis. Patients showing preoperative elevation of CEA and CA
19-9 (Group 3) had a signiﬁcantly worse mean survival (p < 0.01)
than patients presenting with only one elevated tumor marker
above the cut off level (group 2) (28.5 month CI 95% 22.1-35.1 vs.
23.9 month CI 95% 13.9e33.9) [Table 1 and Fig. 1]. This is especiallyFig. 2. Kaplan Meier analysis of patients with PDAC for strue for patients with pT 3/4 tumors as demonstrated in the uni-
variate subgroup analysis [Table 2, Fig. 3]. Furthermore, multivar-
iate analysis identiﬁed preoperative elevated CEA/CA 19-9 levels as
an independent risk factor inﬂuencing patient survival (HR 1.299)
[Table 3].
These ﬁndings correlate well to results in literature. Berger et al.
stratiﬁed 129 surgically resected pancreatic cancer patients into 4ubgroup T 1/2 and subgroups of CEA/CA 19-9 (1e3).
Fig. 3. Kaplan Meier analysis of patients with PDAC for subgroup T 3/4 and subgroups of CEA/CA 19-9 (1e3).
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normal (<37 U/mL), 38e200 U/mL, and >200 U/mL). Patients with
undetectable pre-operative CA 19-9 serum levels and those with
levels of <37 U/mL had an improved median survival (32 and 35
months, respectively) compared to patients with CA 19-9 serum
levels between 38 and 200 U/mL or>200 U/mL (22 and 16 months,
respectively).35 Smith et al. evaluated preoperative CA 19-9 serum
levels in 109 pancreatic cancer patients who underwent a pan-
creatoduodenectomy and noted a median survival of only 10.4
months in patients with a preoperative CA19-9 level >150 U/mL
(n ¼ 64), compared to a median survival of 22.1 months in patients
with a CA19-9 serum level 150 U/mL (n ¼ 45, p ¼ 0.012).36
These studies and our results support the conclusion that
normal or low preoperative levels of CEA and/or CA 19-9 inde-
pendently predict longer survival after curative pancreatic resec-
tion due to PDAC, whereas preoperatively elevated serum levels of
both, CEA/CA 19-9, are associated with a poor prognosis. However,
it has to be kept in mind that due to the different cut off levels usedTable 3
Multivariate analysis of factors that inﬂuence median survival in patients after
pancreatic resection for PDAC.
HR 95% conﬁdence interval HR P value
Lower Upper
Step 1
CEA/CA19-9 (elevated) 1.296 1.124 1.495 <0.001
pT 1/2 0.590 0.359 0.972 0.038
G 3/4 1.282 0.932 1.765 0.127
pNþ 1.461 1.020 2.091 0.038
pMþ 1.070 0.604 1.894 0.817
Step 2
CEA/CA19-9 (elevated) 1.296 1.124 1.494 <0.001
pT 1/2 0.592 0.360 0.974 0.039
G 3/4 1.278 0.930 1.755 0.130
pNþ 1.472 1.035 2.094 0.032
Step 3
CEA/CA19-9 (elevated) 1.299 1.127 1.496 <0.001
pT 1/2 0.595 0.362 0.977 0.040
pNþ 1.470 1.036 2.085 0.031in the literature the comparability of the studies is limited.
Furthermore, due to the retrospective character of this analysis, we
could not determine the ratio of patients receiving adjuvant
chemotherapy. From prior analysis of our database we know that
about 50% of our patients have received adjuvant chemotherapy
and that there is a heterogeneity of the chemotherapeutic regimes
(i.e., mainly gemcitabine).39
Furthermore, in our study the multivariate analysis showed that
T-status (pT 1/2: HR 0.595) and lymphnode involvement (pNþ: HR
1.470) were also factors inﬂuencing patient survival after resection
for PDAC. These results have already been described by other au-
thors like Riediger et al. before.10 Here it is worth mentioning that
especially the lymphnode ratio is crucial as a prognostic factor and
not only the N-status.
5. Conclusion
In conclusion, we could show that preoperatively elevated CEA
and CA 19-9 can be used as additional information to estimate
patients’ prognosis. This is especially true for the most frequent pT
3/4 stages of PDAC. Moreover, T stage and N-status could be iden-
tiﬁed as predictive factors of survival after resection. Although CEA
and CA 19-9 might not be appropriate for screening, its serum
levels should therefore be determined in patients prior to opera-
tion. High preoperative serum levels of CEA and CA 19-9 should be
taken into account by the surgeonwhen resectability or operability
is doubtful.
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